Feb. 3 at 3:31 PM
$SKYE After reading the presentation, it's pathetically obvious SKYE is really trying to get itself acquired. Which fine, they should but, I am not sure anyone is buying what they are selling. The data they recently put out, only has a handful of subjects(20 subjects, 11 for one arm, 9 for the other) to the point we might not be entirely sure that the data is that meaningful. In the presentation they addressed their cash situation, they have a runway of cash until the 4th qtr BUT, that does NOT include any 2b trials that may be required. So figure they have maybe two qtr's of cash left. All we can hope I think is that some Pharma finds Nimicimab interesting enough to take a chance on. Some company might be willing to part with
$250M which in the grand scheme of things isn't a whole lot for an obesity med. So that is what we are hoping for now. I am just not sure this company can go on much further than a few qtr's before some tough questions will need to be answered. I guess we see.
